Related Experiment Video
Updated: Jun 27, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
MicroRNAs in inflammatory bowel disease: What do we know and what can we expect?
Ellen Cristina Souza de Oliveira1, Ana Elisa Valencise Quaglio2, Thais Gagno Grillo1
1Department of Internal Medicine, Medical School, São Paulo State University (Unesp), Botucatu 18618-686, São Paulo, Brazil.
MicroRNAs regulate gene expression and are implicated in inflammatory bowel disease (IBD). Further research is needed to utilize these small RNAs as biomarkers and therapeutic targets for IBD.
Area of Science:
- Molecular Biology
- Genetics
- Immunology
Background:
- MicroRNAs (miRNAs) are small non-coding RNAs regulating over 30% of human genes.
- miRNAs play crucial roles in inflammatory responses and intestinal epithelial cell differentiation.
- Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic gastrointestinal disorder.
Discussion:
- Dysregulated miRNA expression is observed in IBD patients.
- miRNAs are recognized as key regulators in the pathogenesis of IBD.
- Current research highlights the significant, yet not fully understood, involvement of miRNAs in IBD.
Key Insights:
- miRNAs are critical regulators of inflammatory pathways relevant to IBD.
- Altered miRNA profiles are potential indicators for IBD diagnosis and prognosis.
- Despite established roles, clinically applicable miRNA biomarkers for IBD are currently unavailable.
Outlook:
- Further investigation into miRNA function in IBD is essential.
- Discoveries may lead to novel miRNA-based biomarkers for IBD.
- miRNAs show promise as therapeutic targets for personalized IBD treatment.
More Related Videos
08:52Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents